BASEL, SWITZERLAND--(Marketwire - December 07, 2011) -
Basilea Pharmaceutica AG /
Basilea appoints Chief Financial Officer
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basilea Pharmaceutica Ltd. (SIX: BSLN)
today announced that Joachim Blatter has been appointed Chief Financial
(CFO) of Basilea Pharmaceutica International Ltd.
Joachim Blatter will join Basilea mid-January 2012 as Chief Financial
and member of the management committee. In addition to finance he will be
responsible for information technology and internal services reporting to
Operating Officer Ronald Scott, who has been acting as ad interim CFO.
Joachim Blatter, a German citizen, has held various senior finance
most recently as CFO of Swissmetal Industries Ltd. in Dornach, Switzerland.
Blatter was previously CFO of Alcan Singen GmbH and Managing Director of
Holdings Germany GmbH. He holds a degree in business administration from
University of Cologne, Germany, and is a certified management accountant as
as a certified financial manager.
Dr. Anthony Man, Chief Executive Officer, commented: "We are very pleased
welcome Joachim Blatter to Basilea's executive management team as Chief
Financial Officer. He has over 20 years of international experience in
and operational management. In his new position, he will be able to build
Basilea's strong financial foundation with a continued focus on prudent
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
the SIX Swiss Exchange (SIX: BSLN). Basilea Pharmaceutica International
fully integrated research and development operations are focused on
antifungals and oncology drugs, as well as on the development of
drugs, targeting the medical challenge of resistance and non-response to
treatment options in the hospital and specialty care setting.
Basilea is currently marketing Toctino® (alitretinoin), the only
treatment for adults with severe chronic hand eczema unresponsive to potent
topical corticosteroids, in Denmark, Finland, France, Germany, Norway,
Switzerland and the United Kingdom and has appointed distributors for
in other selected European markets, Canada, Israel, Mexico and the Republic
Korea. A phase III clinical program on alitretinoin for the treatment of
chronic hand eczema is ongoing in the U.S.
For its phase III compound isavuconazole, a potential best-in-class azole
antifungal for the treatment of life-threatening invasive fungal
company has entered into a license, co-development and co-promotion
with Astellas Pharma Inc.
In addition, Basilea is developing ceftobiprole, a late-stage novel anti-
(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin
antibiotic, for the first-line treatment of potentially life-threatening
resistant bacterial infections. Ceftobiprole has a broad coverage of both
positive bacteria, including MRSA, and many clinically important Gram-
bacteria such as Pseudomonas spp.
Basilea's BAL30072, a novel antibiotic for the treatment of resistant Gram-
negative infections, and the oncology drug BAL101553 for the treatment of
resistant cancers are in phase I clinical testing.
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different
any future results, performance or achievements expressed or implied by
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE